• MedCana announced in May 2023 full-scale production of non-THC cannabis for export to Europe
• The company earlier in 2023 commenced construction of crop production infrastructure at sites in Central and South America
• MedCana has engaged in talks with the government of Argentina about starting production in that country
• The company in 2023 acquired the assets of Tokan Corp., including an ERP software platform for the cannabis industry

Software Effective Solutions (d/b/a MedCana) (OTC: SFWJ) is a global infrastructure and holding company in the cannabis industry. MedCana currently has five companies focused on pharmaceutical cannabis production, as well a software company focused on managing processes for plant-to-patient operations. The recent acquisition of an irrigation and greenhouse technology company has rounded out MedCana’s portfolio of holdings.

MedCana’s focus is on developing clients and companies in Latin America, initially in Colombia, and partnerships with laboratories, research facilities and hospitals throughout the world. MedCana is building the technology, laboratories, growing facilities and scientific teams to provide premium pharmaceutical-grade cannabis extracts to the world.

MedCana’s goal is to be the world’s premier resource for pharmaceutical cannabis products. The company believes its advantage is its global view and reach. From initial cultivation to final product, MedCana aims to help partners produce pharmaceutical CBD and other extracts that will have no equal.

The company’s mission is to utilize its technology to partner with and develop companies that provide premium pharmaceutical-grade cannabis extracts with absolute integrity, sustainability and social responsibility. MedCana’s team of pharmaceutical scientists includes some of the most respected chemists in the world. They aim to ensure that the company’s customers and partners create premium cannabis extracts that meet the growing worldwide demand. MedCana’s software is designed to ensure traceability and quality from seed to finished product.

MedCana is headquartered in Austin, Texas, with offices in Colombia.

Production

MedCana announced in May 2023 the beginning of full-scale production of non-THC cannabis for export to Europe in response to high demand in that market. This expansion comes after the successful completion of full crop cycle testing and infrastructure development at production sites in Columbia.

The recent acquisition of the assets of Tokan Corp., a software company focused on creating an enterprise resource planning (“ERP”) platform for the cannabis industry, and Eko2O S.A.S., a greenhouse and irrigation engineering company, has positioned MedCana for explosive growth in the region.

As a MedCana subsidiary, Eko2O SA will increase the company’s revenue potential in Central and South America. The subsidiary specializes in the construction and distribution of greenhouses and sophisticated irrigation platforms. A positive outlook has resulted from the company’s expansion as it investigates new opportunities for greenhouse and irrigation system installations in Panama and Uruguay. These opportunities are expected to accelerate Eko2O’s development and strengthen its position as a top supplier of innovative agricultural solutions in cannabis and other sectors that are quickly moving to high technology agricultural production.

In addition, MedCana has started talks with the government in Argentina about possible incentives for beginning operations in that country as part of its ongoing worldwide development strategy. Support from the Argentinean government and the start of new operations there would greatly increase MedCana’s market share in Latin America and solidify the company’s position as the market leader in the cannabis industry.

Market Opportunity

According to a report by Grand View Research, a San Francisco-based market research and consulting company, the global cannabis extract market was valued at $3.5 billion in 2022 and is expected to expand at a CAGR of 20% from 2023 to 2030 to be worth more than $15 billion.

Growing demand for cannabis extracts, including oils and tinctures, and the increased legalization of marijuana for the treatment of different chronic ailments like arthritis, Alzheimer’s, anxiety and cancer are driving the expansion of the industry. The marijuana derivative industry is flourishing due to a greater understanding of its various medical benefits.

Management Team

Jose Gabriel Diaz is CEO of MedCana. He has successfully built, grown and sold multiple telecom companies. He was senior vice president of sales at IP Communications, a national high-speed data provider. He also founded Reallinx, a national data carrier later sold to GTT Communications. Additionally, he is currently president of the A.E.M. Business and Entrepreneurship Association in Austin, Texas.

Claudio Jiménez Cartagena, QF, Ph.D. is Chief Scientific Officer at MedCana. He joined MedCana after working with Sosteli Pharma as Technical Director and serving as a director consultant for the Corporation for Agricultural Industrial Development at the University of Antioquia in Colombia. Before that, he worked as the scientific director at the Institute of Food Science & Technology. He holds a bachelor’s degree in pharmaceutical chemistry, a master’s degree in basic biomedical sciences and a doctoral degree in Environmental Engineering from the University of Antioquia.

Julián Alberto Londoño Londoño, Ph.D., is Senior Vice President of Operations at MedCana. He previously served as general manager for the Corporation for Agricultural Industrial Development, and as Chief Scientific Officer at Sosteli Pharma in the Resource Management Department. He has developed multiple U.S. patents, and recently served as senior advisor to the Secretariat of Agriculture Development for the Government of Antioquia. He holds a doctorate in Chemical Sciences from the University of Antioquia.

For more information, visit the company’s website at www.MedCana.net.

NOTE TO INVESTORS: The latest news and updates relating to SFWJ are available in the company’s newsroom at https://ibn.fm/SFWJ

• Genprex was granted orphan drug designation by the FDA earlier this year for development of REQORSA combined with Tecentriq in small cell lung cancer
• Use of REQORSA combined with Tecentriq is the subject of Genprex’s upcoming Acclaim-3 clinical trial
• Genprex took part in two events in October – the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; and Genprex’s own hosted event, a Virtual Key Opinion Leaders on Bringing Gene Therapy to the Fight Against Lung Cancers

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients living with cancer and diabetes, was granted orphan drug designation (“ODD”) by the US Food and Drug Administration (“FDA”) for its REQORSA(R) immunogene therapy for the combination of its immunogene therapy REQORSA(R) and Genentech Inc.’s Tecentriq(R) as maintenance therapy in patients with extensive stage small cell lung cancer (“SCLC”) who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment earlier this year.

The FDA can grant ODD to a drug or biological product being developed to prevent, diagnose, or treat rare diseases or conditions. The designation is intended to spark innovation among biotech companies developing treatments for the more than 30 million people suffering from rare diseases.

Genprex’s therapy is in development for treating both SCLC and non-small cell lung cancer (“NSCLC”). The company’s Acclaim-1 and Acclaim-2 clinical trials are investigating REQORSA in combination with Tagrisso and Keytruda, respectively, in NSCLC. The company’s Acclaim-3 clinical trial is a Phase 1/2 clinical trial using the combination of immunogene therapy REQORSA(R) and Genentech Inc.’s Tecentriq(R) in patients with extensive stage small cell lung cancer. The Acclaim-3 clinical trial will commence enrollment as soon as reasonably practicable and the company expects this will occur between December 2023 and the end of the first quarter of 2024, subject to the availability of a new manufactured batch of REQORSA.  The Acclaim-1 Phase 2 expansion portion of the trial will also commence enrollment within this time frame, based on the availability of the new REQORSA batch.

“This FDA Orphan Drug Designation, in combination with our recently received FDA Fast Track designation, underscores the great need for better treatment options for patients with ES (extensive-stage)-SCLC and non-small cell lung cancer,” said Rodney Varner, Genprex president, chair, and CEO (https://ibn.fm/n3GXo). “We look forward to initiating the Acclaim-3 clinical trial in order to bring hope of an effective new therapy to patients suffering with this life-limiting cancer.”

Genprex recently took part in two events in October – the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; and Genprex’s own hosted Virtual Key Opinion Leader (“KOL”) Event on Bringing Gene Therapy to the Fight Against Lung Cancers. Each event provided Genprex the opportunity to present its findings in the respective areas.

• 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Genprex presented data on using REQORSA to treat lung cancers (https://ibn.fm/5YzLY). The company presented that the Acclaim-1 Phase 1 study had no dose-limiting toxicity, established a Phase 2 recommended dose, and demonstrated evidence of efficacy of REQORSA in combination with Tagrisso(R). The company’s research collaborators also presented preclinical results showing that REQORSA in combination with a checkpoint inhibitor has anti-tumor activity in a humanized mouse model of SCLC.
• These data and more were highlighted in the company’s recent KOL event: Bringing Gene Therapy to the Fight Against Lung Cancers. The event discussed REQORSA as a potential treatment for NSCLC and SCLC (https://ibn.fm/FnuDk).

The American Cancer Society estimates that almost 127,000 people will die from lung cancer this year, making it one of the most lethal cancers in men and women. SCLC comprises approximately 13% of all lung cancer diagnoses, while NSCLC represents approximately 84% of lung cancer diagnoses (https://ibn.fm/R3mLE). There is currently an unmet need for treatment, which Genprex is on a mission to address.

The company’s oncology pipeline aims to reprogram the course of cancer. The company is evaluating its proprietary, non-viral ONCOPREX(R) Nanoparticle Delivery System, a systemic gene therapy delivery system used in clinical trials for human cancer. It is currently being evaluated in several trials.

For more information, visit the company’s website at www.Genprex.com.

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

• Clene is focused on developing and commercializing novel clean-surfaced nanotechnology (“CSN(R)”) therapeutics
• The company utilizes an electro-crystallization nanotherapeutics platform, which results in nanocrystals that exhibit catalytic activities multiple times higher than numerous other commercially available nanoparticles that the company has comparatively evaluated
• Clene is focusing on central nervous system (“CNS”) disorders like amyotrophic lateral sclerosis (“ALS”), multiple sclerosis (“MS”), and Parkinson’s disease (“PD”)
• Its lead investigational product, CNM-Au8(R), has so far demonstrated a good safety and tolerability profile, with Phase 2 trials suggesting efficacy in ALS patients

Nanotechnology has attracted a great deal of the scientific community’s attention thanks to its ability to deliver medicinally attractive nanoparticles (“NPs”) with promising performances that are directly attributable to such properties as ease of cellular uptake, stability, solubility, synthetic accessibility, and release pattern and cell penetration.

Studies investigating the therapeutic capabilities of metallic NPs such as selenium, silver, and gold, as well as metallic oxides like zinc oxide and aluminum oxide, have documented their potential anti-diabetic, antibacterial, antiviral, and antiparasitic capabilities (https://ibn.fm/OwfF4). Moreover, metallic nanoparticles have been known to have remarkable catalytic activity due to their large surface-area-to-volume ratio compared to the bulk material. This property has led to the development of therapeutic candidates, with Clene (NASDAQ: CLNN), a clinical-stage pharmaceutical company, leading the way.

Clene’s efforts date back to 2013 when the company innovated an electro-crystallization nanotherapeutics platform. The innovation led to the development of novel clean-surfaced nanotechnology (“CSN(R)”) therapeutics that, the company explains (https://ibn.fm/bWoqv), “are comprised of atoms of transition elements that, when assembled in nanocrystal form, possess unusually high, unique catalytic activities not present in those same elements in bulk form.” In fact, Clene underlines that its platform results in nanocrystals that exhibit catalytic activities multiple times higher than numerous other commercially available nanoparticles that the company has comparatively evaluated.

The catalytic activities, the company notes, drive, support, and maintain beneficial metabolic and energetic cellular reactions within diseased, stressed, and damaged cells and have influenced the development of multiple drug candidates, including its lead investigational product, CNM-Au8. The company is currently focusing its efforts on addressing the high unmet medical needs related to CNS disorders like ALS, MS, and PD, conditions that cumulatively affect more than 1.4 million people in the U.S.

CNM-Au8 is a highly concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals that has been the subject of multiple non-clinical studies and clinical trials. Non-clinical toxicology studies, for instance, have demonstrated no adverse effect levels, even when the maximum feasible dosing levels were orally administered. Moreover, in vitro and in vivo pharmacology studies have demonstrated that CNM-Au8 treatment improves neuroprotection and generation of new myelin sheaths around axons of the adult CNS in multiple models of ALS, MS, and PD.

“A Phase I first-in-human study did not reveal safety or tolerability concerns for CNM-Au8 in healthy human volunteers. Similarly, no significant safety signals have been identified across all completed Phase 2 clinical trials in ALS, MS, and PD populations. Two Phase 2 clinical trials in ALS (RESCUE-ALS and the HEALEY ALS Platform Trial) suggested efficacy signals without any significant safety findings,” wrote the company in its 2022 annual report (https://ibn.fm/G8U37).

This September, Clene released long-term follow-up data for patients treated with CNM-Au8 for up to 133 weeks in the open-label extension (“OLE”) of the HEALEY ALS Platform Trial. These results showed significantly improved survival compared to matched placebo controls obtained from the Pooled Resource Open-Access ALS Clinical Trials (“PRO-ACT”) database, the largest U.S. clinical database of previous ALS trials. The follow-up analysis also pooled data from both the HEALEY ALS Platform Trial and the RESCUE-ALS trial, revealing that patients originally randomized to the CNM-Au8 30mg dose demonstrated a statistically significant 59% decreased risk of death compared to matched placebo patients.

“To show such profound survival improvement using the HEALEY ALS Platform Trial dataset alone and a pooled HEALEY and RESCUE dataset is remarkable, and helps confirm the survival benefit seen in the prespecified secondary endpoint. Clene is extremely gratified to see this consistent long-term survival data from the HEALEY ALS Platform Trial OLE, with a continued clean safety profile, adding to the totality of survival evidence,” Benjamin Greenberg, M.D., Head of Medical at Clene, stated in the press release announcing the results of the follow-up analysis (https://ibn.fm/kdskE).

Clene is the sole inventor of its CNS therapeutic drug candidates, as well as the candidates’ manufacturing processes and methods of use. These inventions are protected by a comprehensive intellectual property portfolio of over 150 patents issued worldwide, with about 20 additional patents pending, as of December 31, 2022. The IP portfolio provides a solid foundation for the company‘s planned commercialization of its CSN therapeutics subject to U.S. Food and Drug Administration (“FDA”) approval.

For more information, visit the company’s website at www.Clene.com.

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

• Rare earth element (“REE”) enterprise Ucore Rare Metals Inc. is developing an innovative separation technology for REEs critical to modern computer technologies
• The company is preparing to advance the operational machinery being used to demonstrate Ucore’s proprietary RapidSX(TM) solution side-by-side with conventional separation technology, designing a similar commercial operation that will begin commissioning next year in Louisiana
• China currently dominates the global market for mining, processing, and product creation for REEs, leading to American concerns about vulnerability to price and supply policies controlled by China’s government
• Ucore has received a $4 million award from the U.S. Department of Defense to demonstrate the effectiveness of RapidSX(TM), which includes an additional $10 million for launching the commercial Louisiana operation

Strategic metals supply chain-focused enterprise Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF) is driving American hemisphere innovation in the rare earth element (“REE”) market as a means of protecting Western inventions and technological applications from becoming too vulnerable to The People’s Republic of China’s control over critical resources.

Ucore Chairman and CEO Pat Ryan addressed the company’s development of its proprietary RapidSX(TM) REE processing solution, its preparations to progress from testing at Ucore’s Ontario demonstration plant to a commercial plant in Louisiana, and its savvy use of government funding incentives to move the process as quickly as possible during Ryan’s appearance at Red Cloud’s Fall Mining Showcase 2023.

“Permanent magnets are the things that drive renewable energy. They drive the wind turbines, they drive the electric vehicles (‘EVs’). Those permanent magnets are made with rare earth elements. But the rare earth elements are actually quite controlled by China,” Ryan told RCTV during a Showcase interview (https://ibn.fm/9qwHc). “So resource-side, they control 60 percent of the resource. Separation, mid-stream, 87 percent of the resource, and downstream 90 percent-plus,” he said.

Amid the transition to generating energy from renewable sources, the process is “going to be controlled by China going forward,” Ryan said. “So Ucore’s looked at it and said, ‘Where will we enter the market?’ The most logical place is in the mid-market, the middle of the market where China’s taking control of that 87 percent — use Westernized tech, develop separation for those critical seeds of technology, as the Japanese call it, and that will … connect the bridge between the resource and the downstream magnet makers.”

During his presentation to attendees at the Fall Mining Showcase, Ryan noted that about 90 million vehicles are made each year, and by the end of the decade a third of them are expected to be EVs despite current concerns about cooling trends in the EV market that Ryan labels simple supply and demand adjustments.

He also noted potential national security concerns in that REEs are used in military applications.

“There’s actually 920 pounds of rare earths in an F-35 fighter. Missile guiding systems work because of rare earth permanent magnets. Those rare earths are controlled by China,” he said (https://ibn.fm/takaX).

Ucore’s strategic response is to build three processing plants — the first being the soon-to-launch facility in Louisiana — that allow a “self-use” approach to processing REEs domestically without having to ship it to China first.

“And let’s joint-venture with a couple of mining operations to be able to, in an in situ way, whether it’s in Australia, western Africa, South America, build a plant that works with the mining companies,” Ryan said.

Building a 5,000-ton solvent extraction plant using the industry’s existing conventional separation process (“SX”) would cost $300 million-plus, he said, whereas building a 5,000-ton RapidSX(TM) plant will take about $55 million using a more slender footprint with less demand for electricity.

“Is (commercializing the RapidSX(TM) process) a leap? No, it’s not a leap, because it’s the same chemistry and that chemistry’s proven. But let’s apply it that much more effectively,” Ryan said.

The company has received a $4 million award from the U.S. Department of Defense to demonstrate the effectiveness of RapidSX(TM) in Canada, and anticipates an additional $10 million in funding to help launch the commercial Louisiana operation, he said. Ucore has also been talking with automotive companies about the possibility of reaching pre-purchase supply agreements as an additional form of investing in the company’s future.

For more information, visit the company’s website at www.Ucore.com.

NOTE TO INVESTORS: The latest news and updates relating to UURAF are available in the company’s newsroom at https://ibn.fm/UURAF

• Longeveron recently released topline results from its Phase 2a trial evaluating Lomecel-B(TM) as a potential treatment for mild AD
• The study met its primary safety endpoint across all four study groups and showed positive and statistically significant results in secondary endpoint involving the Composite Alzheimer’s Disease Score (“CADS”) for Lomecel-B(TM) and components of the CADS
• The positive results are expected to form the basis for further development of Lomecel-B(TM) as a potential treatment for mild AD

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions for which there is an unmet medical need, announced on October 5 its topline results from its Phase 2a trial, called the CLEAR MIND trial, investigating Lomecel-B(TM) for the treatment of mild Alzheimer’s disease (“AD”) (https://ibn.fm/b6G9m). The announcement was featured in a recent NetworkNewsAudio (“NNA”) broadcast, which is part of an overall goal to deliver additional visibility, recognition, and brand awareness in the investment community (https://ibn.fm/gSIll).

Lomecel-B(TM) is an allogeneic medicinal signaling cell (“MSC”). MSCs appear to possess anti-inflammatory, pro-vascular, and pro-regenerative properties.

The study met its primary safety endpoint across all study groups based on statistical and medical assessments, with the safety data consistent with an established safety profile with no incidence of hypersensitivity, no cases of Alzheimer Related Imagine Abnormalities (“ARIA”), no clinically asymptomatic microhemorrhages, and no notable changes in laboratory evaluations and electrocardiogram (“ECG”) reported. Moreover, the study revealed statistically significant improvements in the secondary endpoint Composite Alzheimer’s Disease Score (“CADS”) for Lomecel-B(TM) and specific components of the CADS.

“These study results with Lomecel-B(TM) are encouraging,” commented Dr. Jeffrey Cummings, MD, Vice Chair of Research at UNLV’s Department of Brain Health. “The study met its primary safety endpoint and is supported by lack of deterioration in cognitive or atrophy signals. The efficacy observations are encouraging, and these results should be used as a foundation for further studies.”

We believe these results provide important validation of both the safety and therapeutic potential of Lomecel-B(TM) in the treatment of Alzheimer’s Disease, and provide a solid foundation for additional clinical trials in this and other indications,” said Wa’el Hashad, CEO of Longeveron.

Longeveron initiated the CLEAR MIND trial in January 2021 with the aim of obtaining safety and efficacy data following single and multiple infusions of two different dose levels of Lomecel-B(TM) compared to placebo. The study employed a double-blind, 4-arm, parallel design in which 48 patients with mild AD were randomized into the four arms at an allocation ratio of 1:1:1:1, meaning each treatment arm had 12 patients (https://ibn.fm/sBh8e).

In an October 5 webcast during which the company discussed the topline results, Dr. Nataliya Agafonova, Chief Medical Officer of Longeveron, clarified that a total of 49 patients had been treated in the study, 22 being male, with the rest female (https://ibn.fm/ra029). The study was conducted over 45 weeks, which included a 6-week screening period, 12-week treatment period, and 27-week follow-up period.

The study built on positive Phase 1 data reported in 2021 following the completion of the Phase 1 study, which met its primary safety endpoint. Positive secondary efficacy assessments supported the potential therapeutic benefit of Lomecel-B(TM), according to an April 2021 news release (https://ibn.fm/xt78n). Lomecel-B(TM) resulted in a slower decline in cognitive function in patients who received low dose Lomecel-B(TM) compared with placebo. Moreover, quality of life metrics appeared to improve with Longeveron’s Lomecel-B(TM) investigational product as compared to placebo. These results were published in a leading journal, Alzheimer’s and Dementia, the Journal of the Alzheimer’s Association, last year (https://ibn.fm/SLf5q).

Looking ahead, Longeveron plans to announce additional exploratory and biomarker data from the Phase 2a trial which may provide additional insights of the clinical effects of Lomecel-B(TM) in the study population, according to Mr. Hashad.

Investor Contact Mike Moyer LifeSci Advisors Tel: 617-308-4306 Email: mmoyer@lifesciadvisors.com

For more information, visit the company’s website at www.Longeveron.com.

NOTE TO INVESTORS: The latest news and updates relating to LGVN are available in the company’s newsroom at http://ibn.fm/LGVN

Forward-Looking Statements

Certain statements in this press release that are not historical facts are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which reflect management’s current expectations, assumptions, and estimates of future operations, performance and economic conditions, and involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the statements made herein. Forward-looking statements are generally identifiable by the use of forward-looking terminology such as “believe,” “expects,” “may,” “looks to,” “will,” “should,” “plan,” “intend,” “on condition,” “target,” “see,” “potential,” “estimates,” “preliminary,” or “anticipates” or the negative thereof or comparable terminology, or by discussion of strategy or goals or other future events, circumstances, or effects. Factors that could cause actual results to differ materially from those expressed or implied in any forward-looking statements in this release include, but are not limited to, the anticipated use of proceeds from the offering, as well as statements about the ability of Longeveron’s clinical trials to demonstrate safety and efficacy of the company’s product candidates, and other positive results; the timing and focus of the company’s ongoing and future preclinical studies and clinical trials and the reporting of data from those studies and trials; the size of the market opportunity for the company’s product candidates, including its estimates of the number of patients who suffer from the diseases being targeted; the success of competing therapies that are or may become available; the beneficial characteristics, safety, efficacy and therapeutic effects of the company’s product candidates; the company’s ability to obtain and maintain regulatory approval of its product candidates in the U.S., Japan and other jurisdictions; the company’s plans relating to the further development of its product candidates, including additional disease states or indications it may pursue; the company’s plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available and its ability to avoid infringing the intellectual property rights of others; the need to hire additional personnel and the company’s ability to attract and retain such personnel; the company’s estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the company’s need to raise additional capital, and the difficulties it may face in obtaining access to capital, and the dilutive impact it may have on its investors; market and other conditions; the company’s financial performance and ability to continue as a going concern, and the period over which it estimates its existing cash and cash equivalents will be sufficient to fund its future operating expenses and capital expenditure requirements. Further information relating to factors that may impact the company’s results and forward-looking statements are disclosed in the company’s filings with the Securities and Exchange Commission, including Longeveron’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission on March 14, 2023 and its Quarterly Report on Form 10-Q for the third quarter of 2023 filed with the SEC on November 9, 2023. The forward-looking statements contained in this press release are made as of the date of this press release, and the company disclaims any intention or obligation, other than imposed by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

• Sekur, a cybersecurity and internet privacy provider of Swiss-hosted solutions for secure communications and secure data management, is pushing its SekurMessenger amid SEC crackdowns on Wall Street
• The app provides end-to-end encryption, proprietary VirtualVaults, and HelixTech that ensure conversations are secure while also maintaining privacy
• It allows companies on Wall Street to meet the FINRA communication compliance requirements while giving them the overall peace of mind that comes with guaranteed security and encryption
• With this offering, Sekur looks to carve out a significant market share while also asserting itself as a leader in its segment

Sekur Private Data (CSE: SKUR) (OTCQB: SWISF) (FRA: GTD0), a cybersecurity and internet privacy provider of Swiss-hosted solutions for secure communications and secure data management, is offering a secure, easy-to-use, and transparent messaging solution to Wall Street companies amid the U.S. Securities and Exchange Commission (“SEC”) crackdowns. SekurMessenger is an encrypted messaging service that offers full privacy for users, enabled by multiple layers of data protection that guarantee the security of communications (https://ibn.fm/1UsBM).

The SEC has levied over $2.5 billion in fines on Wall Street, the product of two years of investigations into the industry’s use of messaging apps. These investigations have seen major firms such as Wells Fargo, Bank of America, Goldman Sachs, and Morgan Stanley, fined for failing to maintain work-related communications records on their preferred messaging apps. With the institution tightening regulations on internal communication and enforcing them to comply with the Financial Industry Regulatory Authority (“FINRA”), Wall Street has been forced to explore alternatives that meet and exceed the stipulated thresholds.

SekurMessenger is currently available on both iOS and Android and on the web. Features include end-to-end encryption, proprietary VirtualVaults, and HelixTech that ensure conversations are secure while also providing a way to maintain privacy. In addition, any messages or files sent or received between users are stored in a secure cloud hosted on Swiss-based Sekur-owned servers with military-grade security, letting compliance archiving the messages, while users themselves can delete them from their devices, protecting the chats from hacker intrusion (https://ibn.fm/1yWje). Switching to this offering would allow Wall Street companies to meet the communication compliance requirements by FINRA while also giving them a significant head start and the overall peace of mind that comes with guaranteed security and encryption of internal communication.

The SEC’s unrelenting push and crackdown on Wall Street puts even more pressure on companies to comply, and Sekur is looking to take advantage of it. With this initial offering, the company looks to carve out a significant market share, even as it plans to roll out more enterprise-related features, such as a fully private network and mass employee onboarding platform later this year. In addition, the company is asserting itself as a leader in its segment, defining itself as an innovator and trendsetter in its space.

For more information, visit the company’s website at www.Sekur.com.

NOTE TO INVESTORS: The latest news and updates relating to SWISF are available in the company’s newsroom at https://ibn.fm/SWISF

• SuperCom, a global leading provider of traditional and digital identity solutions, just announced its latest order from the Romanian government to the tune of $3.4 million
• SuperCom will help Romania’s Ministry of Interior to bolster its EM project, based on its PureSecurity Suite, covering domestic violence monitoring, GPS tracking of offenders, as well as home detection monitoring
• Deliveries are set to be met by the end of Q4 2023, and SuperCom’s management is optimistic that the order will boost the company’s overall value proposition and lead to many more orders down the line

SuperCom (NASDAQ: SPCB), a leading global provider of traditional and digital identity solutions offering advanced safety, identification, and security products and solutions to governments, recently announced its continued collaboration with the Romanian government. The latest order from the country’s Ministry of Interior is part of an ongoing $30 million project, bolstering the country’s National Electronic Monitoring (“EM”) Project (https://ibn.fm/VALGi).

The EM program is based on SuperCom’s PureSecurity Suite, covering domestic violence monitoring, GPS tracking of offenders, and home detection monitoring. This end-to-end suite offers a secure real-time software platform. Years of testing and on-ground application have proven its effectiveness, affirming SuperCom’s overall approach of designing the suite to meet the unique needs of correctional facilities and law enforcement agencies worldwide.

This new order, valued at $3.4 million, builds on two prior orders from the Romanian government, totaling approximately $15.1 million. According to Ordan Trabelsi, President and CEO of SuperCom, “The recent order, valued at $3.4 million, underscores the caliber of our technology and the unwavering trust our clients have in SuperCom.”

When Romania kicked off its EM project, it looked to cover up to 15,000 enrollees simultaneously across the country. This would also include a unique integration of multiple offenders tracking sub-programs, goals which SuperCom helps them achieve. This latest order further stamps the company’s position as a market leader, offering superior, unrivaled products and services in the EM space.

“This latest order reinforces our status as a global frontrunner in electronic monitoring solutions. At SuperCom, we are dedicated to not only achieving excellent outcomes but also building enduring relationships with governments across the globe,” noted Mr. Trabelsi.

Deliveries are set to be met by the end of the fourth quarter of the 2023 calendar year. SuperCom’s management is optimistic that this order will help boost the company’s overall value proposition, allow for market expansion, and, most importantly, facilitate growth in shareholder value. Having stamped its status as a global frontrunner, the company’s management is confident that this order will lead to many more.

For more information, visit the company’s website at www.SuperCom.com.

NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at http://ibn.fm/SPCB

• Lexaria, a global innovator in drug delivery platforms, has, since 2014, continuously worked on its patented DehydraTECH(TM) drug delivery technology
• The technology has demonstrated overall effectiveness in enhanced delivery of fat-soluble molecules through the human gastrointestinal system, as affirmed by clinical testing
• This overall effectiveness and push for its development has earned Lexaria 37 granted patents globally, with many patents pending
• The company is constantly enhancing its patent portfolio, since granted patents can support an increase in licensing revenue

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, is eyeing growth in license revenue from its intellectual property (“IP”). Since 2014, the company has continuously worked on its flagship technology – the patented DehydraTECH(TM) drug delivery technology – which has demonstrated the improvement of speed of onset, brain absorption, and bioavailability (https://ibn.fm/KSkD1). It is being investigated in association with dementia treatment, nicotine replacement, hypertension, and heart disease treatment, among other applications (https://ibn.fm/ItdVS).

So far, Lexaria has received 37 granted patents globally, with many patents pending. The company is aggressively pushing its patent application process as it recognizes the viable commercial application of its flagship technology. In addition, the company understands that successfully granted patents can lead to an increase in shareholder value as a recognized growing market leader.

“Because of the applicability of DehydraTECH to many market sectors across the globe, we have taken the necessary steps to protect that intellectual property internationally,” notes the company’s 2022 Form 10-K annual report (https://ibn.fm/xxsuF).

Lexaria’s patent portfolio currently spreads across the US, Australia, Japan, Mexico, the European Union, Canada and India. Its strategic approach of filing for applications in lucrative markets is a move to maximize potential revenue for years to come, mainly since out-licensing is a significant revenue stream for the company. DehydraTECH applications have shown that it can be applied in the consumer-packaged goods industry and the drug and pharmaceutical sectors. It has demonstrated suitability in various consumer formats such as oral suspensions, capsules, pills and tablets, nutraceuticals, registered drugs, and topical applications (https://ibn.fm/ZP6LI).

This is all made possible by DehydraTECH’s overall effectiveness in delivering most fat-soluble molecules through the human gastrointestinal system, as demonstrated by its overall effectiveness in crossing the blood-brain barrier once within blood plasma. Test data, both in vitro, in vivo, and human clinical testing, has shown that DehydraTECH reduces the time required to enter the bloodstream. It has also shown an increase in absorption rate, as well as the improvement of the taste and smell of edible products.

“Our current patent portfolio includes patent family applications or grants pertaining to our method of improving bioavailability and taste, and the use of DehydraTECH as a delivery platform for a wide variety of APIs including, but not limited to fat-soluble vitamins; anti-viral drugs; phosphodiesterase inhibitors; human hormones; regulated cannabinoids; and nicotine and its analogs,” notes Lexaria’s most recent Form 10-Q quarterly report (https://ibn.fm/A8THJ).

In June 2023, Lexaria received its latest two granted patents in Canada, bringing the total in the country to five. This followed the staggered receipts of three patents in the country in less than a year, a milestone that recognizes and protects the company’s improved compositions and methods for transdermal and dermal delivery of cannabinoids such as tetrahydrocannabinol (“THC”) and CBD. As it continues to push for more approvals, the company is steadily propping itself up for even more success, stamping its position as a leader in its space. More importantly, it is echoing its commitment to creating shareholder value.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Turbo Energy in September 2023 announced its successful debut on the Nasdaq stock exchange
• The company operates as a subsidiary of Umbrella Solar Investment S.A.
• Turbo Energy’s total revenue for the year ended December 31, 2022, increased by 82% year-over-year to €31,148,676 (approximately $33,321,219)
• In October 2023, the company was awarded a software patent in Spain related to its flagship Sunbox product

Turbo Energy (NASDAQ: TURB) designs, develops and distributes equipment for the generation, management and storage of photovoltaic energy in Spain, Europe and internationally.

Turbo Energy’s products include lithium-ion batteries and inverters. Additionally, the company recently launched its flagship product, the Sunbox, an all-in-one device that integrates most of the equipment required for a residential photovoltaic installation. The Sunbox is powered by AI and features a software system that monitors the generation, use and management of photovoltaic energy by analyzing large amounts of data related to energy generation, consumption, market prices and weather forecasts. This AI system optimizes battery usage, reducing electricity bills and providing peak-use reduction and uninterruptible power supply functions.

Turbo Energy currently sells its photovoltaic energy equipment primarily through distributors for residential consumers in Spain, but it possesses the expertise and international perspective to expand its product portfolio into industrial and commercial scale and markets, as well as advancing the internationalization process it has already started. The company plans to expand into the industrial photovoltaic sector with its new Sunbox, launched in 2023, in higher power and capacity variants. Its goal is to become a significant player in this sector and contribute to the growth of renewable energy solutions.

The company was incorporated in 2013 and is based in Valencia, Spain. It operates as a subsidiary of Umbrella Solar Investment S.A.

Products

Lithium-Ion Batteries

Turbo Energy is one of the leading companies that introduced lithium-ion batteries for photovoltaic energy storage in Spain. Primarily for the home energy storage market, the company’s batteries have capacities from 2.24 kWh to 5.1 kWh in 24 and 48 volts. In addition, its 48V / 5.1 kWh units are available in a dual battery system.

Inverters

The inverter converts the direct current produced by the photovoltaic panels into alternating current that can be used by household appliances. It also regulates battery charging and discharging based on energy needs and optimizes utilization of generated renewable energy. Turbo Energy currently offers multiple models that cover most household installations.

All-in-One Sunbox

This product incorporates inverters, batteries and the rest of the components necessary to operate and protect the photovoltaic installation. This saves installation cost and assembly and configuration time while preventing errors. Notably, the latest Sunbox models also offer an EV charging option.

Software System

In communication with the inverter, the company’s software monitors energy flows between the photovoltaic panels, household consumption, storage and an optional electric vehicle charging station. The software allows users to customize an automatic backup mode based on weather forecasts, or manually select which part of the battery will be reserved for possible power outages. It also allows the battery to be used in a peak shaving mode, which leverages AI to trigger battery power when grid energy is most expensive, effectively reducing the amount of high-cost power drawn from the grid.

Market Opportunity

According to a report by Fortune Business Insights, a global research and reporting firm, the solar energy storage battery market was estimated to be worth $3.33 billion in 2022 and is projected to reach a value of more than $20 billion by 2030, marking a CAGR of 24.2% over the forecast period.

These batteries are crucial components of renewable energy systems, allowing for the storage of excess electricity generated by solar panels, so it can be used during times of no or low sunlight. By storing energy and supplying it when needed, these batteries reduce reliance on the power grid and maximize self-consumption while helping users avoid peak electricity rates. They also contribute to the transition toward a cleaner and more sustainable energy future by enabling residential consumers and businesses to use solar power even when the sun is not shining.

Management Team

Enrique Selva Bellvís is the CEO and founder of the Umbrella Group. In addition, he serves as vice-president of the Valencian Association of Energy Sector Companies industry group. Before his career in the solar energy sector, he was the founder and CEO of Innova Ingenieros Consultores. He holds a degree in industrial engineering with a specialization in energy from the Polytechnic University of Valencia and completed the Management Development Programme at the IESE Business School.

Mariano Soria is the Chief Innovation Officer for the Umbrella Group and serves as General Manager of Turbo Energy. He was CEO of Punt Moble XXI S.L. and continues to serve on that company’s board. Before that, he was the General Manager of REJMAR S.A., a land development company. He received his degree in industrial engineering and industrial organization from the Polytechnic University of Valencia, and his MBA from the European University of Madrid.

Alejandro Moragues is CFO of Turbo Energy. Previously, he held the position of Senior Corporate Auditor for U.S. company Euronet Worldwide Inc. and was an external auditor for PricewaterhouseCoopers. He holds a bachelor’s degree in business administration and management from the Polytechnic University of Valencia.

Manuel Cercos is Chief Commercial Officer at Turbo Energy. Previously, he held positions at Técnicas Aplicadas en Baterías S.L., where he served as Sales Director and Sales Manager. Before that, he worked as a Sales Technician at DAISA.

For more information, visit the company’s website at www.Turbo-e.com.

NOTE TO INVESTORS: The latest news and updates relating to TURB are available in the company’s newsroom at https://ibn.fm/TURB

• SenesTech Inc., a visionary leader in fertility control to manage animal pest populations, has developed products that show success in limiting rat populations using unique non-lethal fertility reduction products
• Rodents are often associated with carrying diseases that can affect humans, and SenesTech’s non-lethal population-reducing technology targets this major problem in a uniquely humane, environmentally conscious, yet effective way
• The Arizona-based company has developed two primary products — its liquid ContraPest(R) brand, and the recently introduced Evolve(TM) Soft Bait formulation, soft bait being favored by rodent control professionals
• The company anticipates using their technology to develop similar pest-control products for other species in the near future

Close on the heels of introducing a new product expected to create exponential revenue growth for the company, pest animal control innovator SenesTech (NASDAQ: SNES) reported its Q3 financial status to investors Nov. 9, highlighting the company’s continued progress in a year that has seen a record sequential quarterly increase in its earnings.

An archived recording of the Q3 report can be found on SenesTech’s Investor Relations page, at https://ibn.fm/AeEie.

SenesTech’s commitment to sustainable, non-toxic rodent reduction, is reflected in the company’s drive to market a global pest solution that introduces fertility control as the ideal alternative to toxic poisons.

Its trademarked liquid ContraPest(R) bait and Evolve(TM) Soft Bait both target the rapid birth rate in rodent populations, which can result in 15,000 offspring for a single pair of breeding rats in a year’s time and half a billion descendants within three years, according to research cited by President & CEO Joel Fruendt during an October webcast also available on the company’s archived recording webpage.

ContraPest established the company’s reputation with a brand that has shown success in reducing rat populations and subsequently increasing the profitability of poultry enterprises on both the East and West Coasts. The pest control industry’s preference for non-liquid applications then led SenesTech to formulate a non-liquid soft bait solution in its new Evolve product.

“Evolve was developed to offer customers a soft bait product that has similar efficacy to ContraPest(R), but in a format that is easier to deploy and that they can use daily in their integrated pest management programs,” Fruendt stated in a Nov. 1 news release announcing that the company is now taking orders from commercial customers for the soft bait formulation (https://ibn.fm/guMGb).

“Evolve is also suited for use by consumers,” he added, “and we expect to announce partnerships with e-commerce providers and big box retailers by the end of the year.”

The company states that Evolve is highly palatable to rats, and can be placed virtually anywhere rats are found, ranging from outdoor parks and recreation facilities to medical facilities and residential locations.

Evolve currently is only formulated for rats, although the company expects to expand to other pest species in the near future. The product’s active ingredient is a compound derived from cottonseed oil administered in doses too low to affect other species’ fertility as long as the product isn’t consumed in substantial quantities over extended periods of time, but the company recommends using tamper-resistant bait stations to minimize potential non-target species exposure.

Evolve is designed for repeated application. Its non-lethal approach to rodent birth control anticipates a cumulative effect over time with a half-life of approximately three days after consumption, and the company states rats will regain their fertility within approximately six weeks after they stop consuming the bait.

With the advent of cooler weather in the Northern Hemisphere, rodent activity becomes more noticeable because of their efforts to find warm refuge. An estimated 21 million homes across the United States will be affected by rodent activity during the season, according to pest control corporation Orkin (https://ibn.fm/ASt6r).

SenesTech’s original liquid ContraPest brand has the benefit of targeting hard-to-get roof rodents, and is the only rat contraception product for both male and female rats registered with the Environmental Protection Agency (“EPA”).

For more information, visit the company’s website at www.SenesTech.com.

NOTE TO INVESTORS: The latest news and updates relating to SNES are available in the company’s newsroom at https://ibn.fm/SNES